Regulation and function of Rankl in arterial calcification

Belinda A. Di Bartolo, Mary M. Kavurma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Receptor activator of nuclear factor-κB ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL-mediated signalling may help develop more sophisticated cell-based therapies to inhibit calcification of the vessel wall.

LanguageEnglish
Pages5853-5861
Number of pages9
JournalCurrent Pharmaceutical Design
Volume20
Issue number37
Publication statusPublished - 1 Mar 2014
Externally publishedYes

Keywords

  • Arterial calcification
  • Osteoprotegerin (OPG)
  • Receptor activator of nuclear factor-κB ligand (RANKL)
  • Tumour necrosis factor-related apoptosisinducing ligand (TRAIL)

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Di Bartolo, B. A., & Kavurma, M. M. (2014). Regulation and function of Rankl in arterial calcification. Current Pharmaceutical Design, 20(37), 5853-5861.
Di Bartolo, Belinda A. ; Kavurma, Mary M. / Regulation and function of Rankl in arterial calcification. In: Current Pharmaceutical Design. 2014 ; Vol. 20, No. 37. pp. 5853-5861.
@article{764673968ed84e81a8f2958c919d9289,
title = "Regulation and function of Rankl in arterial calcification",
abstract = "Receptor activator of nuclear factor-κB ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL-mediated signalling may help develop more sophisticated cell-based therapies to inhibit calcification of the vessel wall.",
keywords = "Arterial calcification, Osteoprotegerin (OPG), Receptor activator of nuclear factor-κB ligand (RANKL), Tumour necrosis factor-related apoptosisinducing ligand (TRAIL)",
author = "{Di Bartolo}, {Belinda A.} and Kavurma, {Mary M.}",
year = "2014",
month = "3",
day = "1",
language = "English",
volume = "20",
pages = "5853--5861",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "37",

}

Di Bartolo, BA & Kavurma, MM 2014, 'Regulation and function of Rankl in arterial calcification', Current Pharmaceutical Design, vol. 20, no. 37, pp. 5853-5861.

Regulation and function of Rankl in arterial calcification. / Di Bartolo, Belinda A.; Kavurma, Mary M.

In: Current Pharmaceutical Design, Vol. 20, No. 37, 01.03.2014, p. 5853-5861.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulation and function of Rankl in arterial calcification

AU - Di Bartolo, Belinda A.

AU - Kavurma, Mary M.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Receptor activator of nuclear factor-κB ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL-mediated signalling may help develop more sophisticated cell-based therapies to inhibit calcification of the vessel wall.

AB - Receptor activator of nuclear factor-κB ligand (RANKL) is a member of the tumour necrosis factor family important in bone remodelling. Recent evidence suggest that calcification in the vessel wall is equivalent to mechanisms mediating bone formation. This review highlights the role of RANKL in vascular arterial calcification. Here, the relationship between RANKL, osteoprotegerin (OPG) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is discussed. Furthermore, we focus on the regulatory mechanisms mediating RANKL gene expression and transcription in cells of the vessel wall. A better understanding of RANKL-mediated signalling may help develop more sophisticated cell-based therapies to inhibit calcification of the vessel wall.

KW - Arterial calcification

KW - Osteoprotegerin (OPG)

KW - Receptor activator of nuclear factor-κB ligand (RANKL)

KW - Tumour necrosis factor-related apoptosisinducing ligand (TRAIL)

UR - http://www.scopus.com/inward/record.url?scp=84911466832&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 5853

EP - 5861

JO - Current Pharmaceutical Design

T2 - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 37

ER -

Di Bartolo BA, Kavurma MM. Regulation and function of Rankl in arterial calcification. Current Pharmaceutical Design. 2014 Mar 1;20(37):5853-5861.